Compare MMT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMT | TNXP |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.7M | 172.7M |
| IPO Year | N/A | 2008 |
| Metric | MMT | TNXP |
|---|---|---|
| Price | $4.61 | $14.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 118.2K | ★ 487.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $15.37 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $4.37 | $11.60 |
| 52 Week High | $4.87 | $69.65 |
| Indicator | MMT | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 51.62 |
| Support Level | $4.37 | $13.32 |
| Resistance Level | $4.72 | $20.36 |
| Average True Range (ATR) | 0.06 | 1.01 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 35.97 | 74.83 |
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, automotive, chemicals, electronics, and others.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.